{"title":"Fabrication of nano-ceria encapsulated with oleic acid to attenuate gestational diabetes mellitus in streptozotocin-induced diabetic pregnant mice model.","authors":"Huili Yang, Yujun An, Juan Meng, Xiaomei Lv","doi":"10.1080/02652048.2024.2423629","DOIUrl":"10.1080/02652048.2024.2423629","url":null,"abstract":"<p><strong>Aim: </strong>The study aims to fabricate and evaluate Nano-ceria encapsulated oleic acid (CeO<sub>2</sub> NPs-OA) to treat gestational diabetes mellitus (GDM).</p><p><strong>Methods: </strong>The CeO<sub>2</sub> NPs was synthesised by thermal decomposition. TEM, XRD, and FTIR confirms particles. <i>In vitro</i> studies on STZ-induced NIH 3T3 assessed antioxidant, anticancer, antidiabetic, and anti-inflammatory properties. <i>In vivo</i> studies were performed on pregnant mice induced with STZ, examined antidiabetic activity, oxidative stress, and dyslipidemia.</p><p><strong>Results: </strong>The CeO<sub>2</sub> NPs-OA had a spherical structure and uniform distribution. A PDI of 0.5 with a zeta-potential of - 44 ± 2 mV. The DPPH and ABTS exhibit 40% and 39.21% antioxidant activity. The CeO<sub>2</sub> NPs-OA inhibits diabetes at 500 μg/mL. The <i>in vivo</i> studies confirmed the reduction in oxidative stress by reducing MDA <i>(p < 0.05)</i>. The histopathological analysis of the STZ-induced model shows capillary, which CeO<sub>2</sub> NPs-OA reduced.</p><p><strong>Conclusion: </strong>CeO<sub>2</sub> NPs-OA shows promise for treating GDM and improving maternal and foetal health.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"191-208"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Weina Liang, Yan Zhang, Jianpeng Li, Chenglin Ji, Xuexin Jiang
{"title":"Her-2 nanobody modified cisplatin nanoparticles for precise chemotherapy of colon cancer.","authors":"Weina Liang, Yan Zhang, Jianpeng Li, Chenglin Ji, Xuexin Jiang","doi":"10.1080/02652048.2025.2467060","DOIUrl":"10.1080/02652048.2025.2467060","url":null,"abstract":"<p><p>Construct a Her-2 nanobody modified nanoplatform as a versatile carrier of cisplatin and evaluate its anti-tumour effects. Size, morphology, cellular uptake, in vitro release, cell viability, bio-distribution and antitumor efficacy were respectively measured by dynamic light scattering, transmission electron microscopy, confocal microscopy, HPLC, MTT assay, ICP-Mass and tumour volume. Nb-CDDP NPs was prepared with average diameter 60.4 ± 8.4 nm, PDI 0.2 ± 0.02, Zeta potential -35.74 mV, entrapment efficiency 89.5%±0.8% and drug loading 28.7%±1.3% (w/w). From which cisplatin could release more rapidly in acidic solution. NPs could be easily phagocytised and exhibited stronger cytotoxic effect in HCT-116 cells with IC<sub>50</sub> 1.46 ± 0.019 μg/mL. The concentration of Nb-CDDP NPs in tumour and its inhibition ratio on tumour volume were both higher than without Nb modification, with hardly any influence on body weight. This cisplatin nanoplatform exhibits exceptional properties and high targeting anti-tumour efficacy in colon cancer cells and mice, which maybe provide a promising strategy for precise chemotherapy.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"230-238"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synergistic combinatorial delivery system based on nanoliposome encapsulating doxorubicin and sorafenib for broad-spectrum cancer treatment.","authors":"Farwa Nurjis, Usama Sarwar, Joham Sarfraz Ali, Mahnoor Fayyaz, Faiza Munir, Shaheen Shahzad","doi":"10.1080/02652048.2025.2480597","DOIUrl":"10.1080/02652048.2025.2480597","url":null,"abstract":"<p><p>A novel combination delivery approach entrapping Sorafenib inside a nanoliposome bilayer and Doxorubicin within the aqueous core to achieve the broad-spectrum synergistic chemotherapeutic effect. DOX-SOR liposomes were synthesized by thin film hydration and characterized using UV-visible spectroscopy, Fourier Transform Infrared Spectroscopy, Dynamic Light Scattering, Fluorescence, and Scanning Electron Microscopy, followed by cytotoxicity assessments. Nanoliposomes demonstrated effective loading and encapsulation of Doxorubicin (10.23% ± 0.65 and 89.65% ± 0.52) and Sorafenib (10.42% ± 0.50 and 85.35% ± 0.72) with a 165 nm ± 1.34 mean diameter, -15.2 ± 1.78 zeta potential, and 75% ± 1.92 of cumulative release. <i>In vitro</i> analysis of nanoliposomes demonstrated biocompatibility up to 250 µg/mL concentration (<i>p</i> < 0.05), enhanced intracellular localization in Hep2c cell lines, 91% ± 1.72 cytotoxic effects (<i>p</i> < 0.0001) with IC<sub>50</sub> up to 127µg/mL, 21% ± 0.89 cell viability with 85% apoptosis (<i>p</i> < 0.0001) using flow cytometer. This study presents a promising treatment approach using a multidrug-loaded nanoliposomes for broad-spectrum synergistic chemotherapy.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"300-312"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hanaa Ali Hussein, Fatin L Khaphi, Ramachandran Sivaramakrishnan, Sivamani Poornima, Mohd Azmuddin Abdullah
{"title":"Recent developments in sustained-release and targeted drug delivery applications of solid lipid nanoparticles.","authors":"Hanaa Ali Hussein, Fatin L Khaphi, Ramachandran Sivaramakrishnan, Sivamani Poornima, Mohd Azmuddin Abdullah","doi":"10.1080/02652048.2025.2495290","DOIUrl":"https://doi.org/10.1080/02652048.2025.2495290","url":null,"abstract":"<p><p>Solid Lipid Nanoparticles (SLNs) are versatile nano-carriers for wide range of applications. The advantages of SLNs include ease of preparation, low toxicity, high active compound bioavailability, flexibility of incorporating hydrophilic and lipophilic drugs, and feasibility of large-scale production. This review provides an overview on the preparation methods of the SLNs, the micro and nanostructure characteristics of the SLNs, and the different factors influencing sustained release and targeted drug delivery. The applications in agriculture and environment, cosmetics, wound healing, malarial treatment, gene therapy and nano-vaccines, and cancer therapy, are elaborated. The mechanisms such as passive, active, and co-delivery are discussed. The issues, challenges and the way forward with ionisable SLNs for delivery of gene and vaccines, RAS-targeted therapy, and bioactive compounds, are highlighted. In combination with multiple compounds and the potential for integration with nature/bio-based solutions, SLNs are proven to be effective, and practical for diverse applications.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"1-31"},"PeriodicalIF":3.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel formulation of curcumin-loaded chlorhexidine drug combined with gold nanoparticles for effective therapeutic agent against urinary tract infections.","authors":"Jian Kang, Yanqing Tong","doi":"10.1080/02652048.2025.2457667","DOIUrl":"10.1080/02652048.2025.2457667","url":null,"abstract":"<p><strong>Aim: </strong>This study investigates a novel treatment for urinary tract infections (UTIs) caused by <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, and <i>Klebsiella pathogenic</i> bacterial strains.</p><p><strong>Methods: </strong>The Cur/Chx/Au composite matrix was synthesised in one pot by solution reduction and examined for functional groups and surface morphology by FT-IR, UV-DRS, HR-TEM, and TGA. <i>In vitro,</i> microbial growth inhibition evaluation and pathogen biofilm studies assessed the composite's antibacterial capacity.</p><p><strong>Results: </strong>Cur/Chx/Au exhibit mean diameter from 30 ± 5.2 nm, PDI 0.50 ± 0.05, and a zeta potential of -9.56 ± 1.84. The inhibition zones for <i>S. aureus</i> and <i>E. coli</i> were 16 ± 1.2 mm and 14 ± 0.8 mm, respectively, with an anti-inflammatory inhibition rate of 89.96%. The composite material's biocompatibility was further tested utilising <i>in-vitro</i> MTT, cell proliferation, and wound scratch assays in NHI 3T3 cells.</p><p><strong>Conclusion: </strong>Our findings demonstrate that the combination of Cur/Chx/Au composite matrix is a promising formulation for UTI treatment.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"177-190"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zainab Muhammad, Suleiman A Muhammad, Abdullahi Y Abbas, Mohammed Achor, Samson A Adeyemi, Yahya E Choonara, Yusuf Saidu, Lawal S Bilbis
{"title":"Isolation and characterization of medicinal plant-based extracellular vesicles as nano delivery systems for ascorbic acid.","authors":"Zainab Muhammad, Suleiman A Muhammad, Abdullahi Y Abbas, Mohammed Achor, Samson A Adeyemi, Yahya E Choonara, Yusuf Saidu, Lawal S Bilbis","doi":"10.1080/02652048.2024.2443430","DOIUrl":"10.1080/02652048.2024.2443430","url":null,"abstract":"<p><strong>Aim: </strong>Plant-derived extracellular vesicles (EVs) are natural nanovesicles for drug delivery. This study isolated and characterised EVs from medicinal plants as delivery vehicles.</p><p><strong>Methods: </strong>Precipitation method was employed for the isolation and characterised using DLS, SEM, and TEM. The encapsulation efficiency (EE) and antioxidant activity of ascorbic acid (AA)-EVs were evaluated.</p><p><strong>Results: </strong>The total yields of lyophilised vesicles per weight of the sample were 6.0, 8.6 and 9.2 mg/g for garlic, turmeric and ginger, respectively. Mean size of garlic-derived EVs, ginger-derived EVs, and turmeric-derived EVs were 101.0 ± 6.7, 226.4 ± 62.2 and 90.7 ± 2.5 nm, respectively. The zeta potential of the EVs was between -33.2 ± 10.9 and -28.8 ± 8.43 mV. Spherical morphology of the nanovesicles was confirmed by SEM and TEM. The EE of the EVs was between 78.1 ± 2.8% and 87.2 ± 1.4%.</p><p><strong>Conclusion: </strong>Overall, the antioxidant activity of AA-loaded EVs was better compared to free AA. This study provides evidence that these medicinal plants are rich sources for developing nanotherapeutics.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"120-131"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ebru Kilicay, Ebru Erdal, Özge Kübra Karadag, Baki Hazer
{"title":"Evaluation of the antimicrobial and anticancer potential of a modified silver nanoparticle-impregnated carrier system.","authors":"Ebru Kilicay, Ebru Erdal, Özge Kübra Karadag, Baki Hazer","doi":"10.1080/02652048.2024.2443437","DOIUrl":"10.1080/02652048.2024.2443437","url":null,"abstract":"<p><p>This study aimed to develop silver nanoparticles embedded in poly(ricinoleic acid)-poly(methyl methacrylate)-poly(ethylene glycol) (AgNPsPRici-PMMA-PEG) nanoparticles (NPs) containing caffeic acid (Caff) and tetracycline hydrochloride (TCH) for treating infections and cancer in bone defects. The block copolymers were synthesised via free radical polymerisation. NPs were prepared using the solvent evaporation method and characterised by FTIR, HNMR, SEM, DSC, TGA, and DLS. Drug loading (LE), encapsulation efficiency (EE), antimicrobial activity, cytotoxicity, and <i>in vitro</i> release studies were conducted. The NPs exhibited a size of 198 ± 2.89 nm, a narrow size distribution (PDI < 0.1), and a zeta potential of -27.5 ± 0.13 mV. The EE of Caff were 73 ± 0.09% w/w and 78 ± 0.32% w/w. Caff NPs showed prolonged release (69 ± 0.23% w/w), cytotoxicity with the cell viability of 66.85 ± 10.51% in SaOS cells, and antimicrobial zones ranging from 1.5 ± 0.3 to 4.2 ± 0.2 mm. TCH-Caff-AgNPsPRici-PMMA-PEG NPs exhibited promising therapeutic potential for infection and cancer treatment in bone defects.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"142-160"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Encapsulation of anti-VEGF nanobody into niosome nanoparticles: a novel approach to enhance circulation half life and efficacy.","authors":"Mohsen Chiani, Raha Abedini, Reza Ahangari-Cohan, Mahdi Behdani, Seyed Mahmoud Barzi, Nastaran Mohseni, Fatemeh Kazemi-Lomedasht","doi":"10.1080/02652048.2024.2443435","DOIUrl":"10.1080/02652048.2024.2443435","url":null,"abstract":"<p><p>This study aimed to encapsulate an anti-VEGF nanobody (Nb) within niosome nanoparticles (NNPs) to enhance its circulation half life. Key parameters such as encapsulation efficiency, stability, Nb release, cytotoxicity, and cell migration inhibition in HUVEC cells were evaluated, along with pharmacokinetic studies in mice. Nb-loaded NNPs (Nb-NNPs) were successfully prepared with an encapsulation efficiency of 78.3 ± 3.2% and demonstrated stability over one month. <i>In vitro</i> assays revealed that Nb-NNPs enhanced cytotoxicity and significantly reduced cell migration in HUVEC cells compared to free Nb (<i>P</i> < 0.05). Pharmacokinetic studies in mice demonstrated a dramatically reduced elimination rate constant (0.025 h<sup>-1</sup> vs. 0.843 h<sup>-1</sup>) and an extended terminal half life (27.721 h vs. 0.822 h), indicating slower clearance and prolonged systemic presence. In conclusion, these findings underscore the potential of Nb-NNPs to provide sustained and potent therapeutic effects, contributing valuable insights for advancing targeted therapeutic strategies.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"132-141"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hitesh Kumar Dewangan, Kamal Shah, Anil Kumar Vadaga, Manisha Veer, Perwez Alam
{"title":"Optimisation and evaluation of long circulating Ru-SLNs carrier for targeting melanoma cells.","authors":"Hitesh Kumar Dewangan, Kamal Shah, Anil Kumar Vadaga, Manisha Veer, Perwez Alam","doi":"10.1080/02652048.2024.2443436","DOIUrl":"10.1080/02652048.2024.2443436","url":null,"abstract":"<p><p>The aim of study was to prepared and evaluated rutin-loaded solid-lipid-nanoparticles (Ru-SLNs) gel for treatment of melanoma cells. SLNs were prepared by ultrasonication method through optimisation and evaluated their mean-diameter, PDI, zeta-potential, morphology, entrapment-efficiency, drug-loading, interaction by FTIR, in vitro skin permeation, stability, antioxidant/MTT assay and fluorescence microscopic. Further developed Ru-SLNs was incorporated into gel and characterised their physicochemical properties, drug contents, in vitro diffusion, ex vivo permeation and retention studies in human cadaver skin. Optimised Ru-SLNs batch showed 556.4 <b>±</b> 2.6 nm mean-diameter, -21.9 mV zeta-potential, 94.8 ± 04% entrapment-efficiency, 62.3 ± 29% loading, and 86.63% release after 6 hrs. MTT assay showed, Ru-SLNs have 15.37 times more effectiveness against melanoma cells, while fluorescence microscopy confirmed the cellular uptake over time. Gel based Ru-SLNs, have reduction in flux across skin, indicating a sustained release of rutin and higher retention within the deeper epidermis layer. Finally, Ru-SLNs based gel exhibited promising potential and effectively targeting to skin's epidermal layer for melanoma cells.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"107-119"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Walid Anwar, Abdulsalam M Kassem, Ayman Salama, Mohamed F Zidan, Ahmed H Ibrahim, Ibrahim A Elbahwy, Elsaied H Barakat, Tarek M Faris, Maged K Elsayad, Ahmed M Samy, Mahmoud M A Elsayed, Abdelaziz E Abdelaziz
{"title":"Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriers.","authors":"Walid Anwar, Abdulsalam M Kassem, Ayman Salama, Mohamed F Zidan, Ahmed H Ibrahim, Ibrahim A Elbahwy, Elsaied H Barakat, Tarek M Faris, Maged K Elsayad, Ahmed M Samy, Mahmoud M A Elsayed, Abdelaziz E Abdelaziz","doi":"10.1080/02652048.2025.2451848","DOIUrl":"10.1080/02652048.2025.2451848","url":null,"abstract":"<p><p>This study evaluated albendazole (ABZ) nanostructured lipid carriers (NLCs) for hepatocellular carcinoma treatment. ABZ-NLCs were prepared using emulsification-ultrasonication and optimised using a Box-Behnken design. Independent variables-lipids concentration (X<sub>1</sub>), surfactant concentration (X<sub>2</sub>), and sonication duration (X<sub>3</sub>)-were assessed for their effect on mean diameter (Y<sub>1</sub>), PDI (Y<sub>2</sub>), and entrapment efficiency (Y<sub>3</sub>). The optimised formulation exhibited a mean diameter of 166.13 ± 3.72 nm, a PDI of 0.17 ± 0.01, a zeta potential of -39.86 ± 1.84 mV, an entrapment efficiency of 94.25 ± 6.12%, and a loading capacity of 99.93 ± 7.15 mg/g. Following chitosan coating (ABZ-CS-NLCs), all parameters were maintained, and the zeta potential developed to +24.61 ± 1.32 mV, improving cellular interaction. The cytotoxicity assays revealed that ABZ-CS-NLCs were more effective than uncoated NLCs and free ABZ, with an IC50 value of 8.89 μM in HepG2 cells. Overall, ABZ-CS-NLCs demonstrate a promising and effective delivery platform for targeted hepatic cancer therapy.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"161-176"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}